Amantadine protects dopamine neurons by a dual action: Reducing activation of microglia and inducing expression of GNDF in astroglia

Neuropharmacology

Volumn 61, Issue 4, 2011, Pages 574-582

  Ossola, Bernardino ^a,b   Schendzielorz, Nadia ^a,b   Chen, Shih Heng ^b   Bird, Gary S ^b   Tuominen, Raimo K ^a   Männistö, Pekka T ^a   Hong, Jau Shyong ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

In vitro model; LPS; MPP+; Neurodegenerative disease; Neuroinflammation; Neuroprotection; Parkinson's disease

Indexed keywords

AMANTADINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL TYPE; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; FEMALE; MACROGLIA; MESENCEPHALON; MICROGLIA; NERVE CELL STIMULATION; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT;

AMANTADINE; ANIMALS; ANIMALS, NEWBORN; ASTROCYTES; CELLS, CULTURED; COCULTURE TECHNIQUES; DOPAMINE; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; INFLAMMATION MEDIATORS; MICROGLIA; NEURAL INHIBITION; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PREGNANCY; RATS; RATS, INBRED F344;

EID: 80955179603     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2011.04.030     Document Type: Article

References (41)

1. W.E. Bleidner, J.B. Harmon, W.E. Hewes, T.E. Lynes, and E.C. Hermann Absorption, distribution and excretion of amantadine hydrochloride J. Pharmacol. Exp. Ther. 150 1965 484 490
2. M.L. Block NADPH oxidase as a therapeutic target in Alzheimer's disease BMC Neurosci. 9 Suppl 2 2008 S8
3. M.L. Block, L. Zecca, and J.S. Hong Microglia-mediated neurotoxicity: uncovering the molecular mechanisms Nat. Rev. Neurosci. 8 2007 57 69 (Pubitemid 46011999)
4. A.S. Caumont, J.N. Octave, and E. Hermans Amantadine and memantine induce the expression of the glial cell line-derived neurotrophic factor in C6 glioma cells Neurosci. Lett. 394 2006 196 201 (Pubitemid 43144849)
5. P. Chan, D.A. Di Monte, J.W. Langston, and A.M. Janson (+)MK-801 does not prevent MPTP-induced loss of nigral neurons in mice J. Pharmacol. Exp. Ther. 280 1997 439 446 (Pubitemid 27171432)
6. H.S. Chen, J.W. Pellegrini, S.K. Aggarwal, S.Z. Lei, S. Warach, F.E. Jensen, and S.A. Lipton Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity J. Neurosci. 12 1992 4427 4436
7. W. Danielczyk Twenty-five years of amantadine therapy in parkinson's disease J. Neural Transm. Suppl. 46 1995 399 405 (Pubitemid 26043245)
8. W. Danysz, C.G. Parsons, J. Kornhuber, W.J. Schmidt, and G. Quack Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies Neurosci. Biobehav. Rev. 21 1997 455 468 (Pubitemid 27255850)
9. C.L. Darlington Astrocytes as targets for neuroprotective drugs Curr. Opin. Investig. Drugs 6 2005 700 703 (Pubitemid 40904040)
10. N.L. Diaz, and C.H. Waters Current strategies in the treatment of parkinson's disease and a personalized approach to management Expert Rev. Neurother 9 2009 1781 1789
11. H.M. Gao, J.S. Hong, W. Zhang, and B. Liu Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons J. Neurosci. 22 2002 782 790 (Pubitemid 34141759)
12. H.M. Gao, J. Jiang, B. Wilson, W. Zhang, J.S. Hong, and B. Liu Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to parkinson's disease J. Neurochem. 81 2002 1285 1297 (Pubitemid 34809262)
13. M.B. Hesselink, B.G. De Boer, D.D. Breimer, and W. Danysz Brain penetration and in vivo recovery of NMDA receptor antagonists amantadine and memantine: a quantitative microdialysis study Pharm. Res. 16 1999 637 642 (Pubitemid 29227091)
14. R. Inzelberg, U. Bonuccelli, E. Schechtman, A. Miniowich, R. Strugatsky, R. Ceravolo, C. Logi, C. Rossi, C. Klein, and J.M. Rabey Association between amantadine and the onset of dementia in parkinson's disease Mov. Disord. 21 2006 1375 1379 (Pubitemid 44613288)
15. J. Kornhuber, G. Quack, W. Danysz, K. Jellinger, W. Danielczyk, W. Gsell, and P. Riederer Therapeutic brain concentration of the NMDA receptor antagonist amantadine Neuropharmacology 34 1995 713 721
16. A.E. Lang, and R.D. Blair Anticholinergic drugs and amantadine in the treatment of parkinson's disease D.B. Calne, Drugs for the Treatment of Parkinson's Disease 1989 Springer-Verlag New York 307 323
17. H. Leone, and B.W. Polsonetti Amantadine for traumatic brain injury: does it improve cognition and reduce agitation? J. Clin. Pharm. Ther. 30 2005 101 104 (Pubitemid 41583603)
18. J.P. Lievremont, G.S. Bird, and J.W. Putney Jr. Mechanism of inhibition of TRPC cation channels by 2-aminoethoxydiphenylborane Mol. Pharmacol. 68 2005 758 762 (Pubitemid 41206029)
19. C.J. Lin, Y. Tai, M.T. Huang, Y.F. Tsai, H.J. Hsu, K.Y. Tzen, and H.H. Liou Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents J. Neurochem. 114 2010 717 727
20. Y. Liu, L. Qin, G. Li, W. Zhang, L. An, B. Liu, and J.S. Hong Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation J. Pharmacol. Exp. Ther. 305 2003 212 218 (Pubitemid 36373853)
21. M.R. Luquin, L. Saldise, J. Guillen, S. Belzunegui, W. San Sebastian, A. Izal, P. Garrido, and M. Vazquez Does increased excitatory drive from the subthalamic nucleus contribute to dopaminergic neuronal death in parkinson's disease? Exp. Neurol. 201 2006 407 415 (Pubitemid 44344233)
22. H.S. Lustig, K.V. Ahern, and D.A. Greenberg Antiparkinsonian drugs and in vitro excitotoxicity Brain Res. 597 1992 148 150
23. E.R. Matarredona, M. Santiago, A. Machado, and J. Cano Lack of involvement of glutamate-induced excitotoxicity in MPP+ toxicity in striatal dopaminergic terminals: possible involvement of ascorbate Br. J. Pharmacol. 121 1997 1038 1044 (Pubitemid 27277802)
24. D. Merims, H. Shabtai, A.D. Korczyn, C. Peretz, N. Weizman, and N. Giladi Antiparkinsonian medication is not a risk factor for the development of hallucinations in parkinson's disease J. Neural Transm. 111 2004 1447 1453 (Pubitemid 39468398)
25. H.J. Otton, A.L. McLean, M.A. Pannozzo, C.H. Davies, and D.J. Wyllie Quantification of the mg(2)-induced potency shift of amantadine and memantine voltage-dependent block in human recombinant GluN1/GluN2A NMDARs Neuropharmacology 60 2010 388 396
26. R. Pahwa, S.A. Factor, K.E. Lyons, W.G. Ondo, G. Gronseth, H. Bronte-Stewart, M. Hallett, J. Miyasaki, J. Stevens, W.J. Weiner Quality Standards Subcommittee of the American Academy of Neurology Practice parameter: treatment of parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 66 2006 983 995 (Pubitemid 44044780)
27. G. Quack, M. Hesselink, W. Danysz, and R. Spanagel Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover J. Neural Transm. Suppl. 46 1995 97 105 (Pubitemid 26043225)
28. D.M. Robinson, and G.M. Keating Memantine: a review of its use in Alzheimer's disease Drugs 66 2006 1515 1534 (Pubitemid 44250755)
29. Z. Rogoz, G. Skuza, W.A. Daniel, J. Wojcikowski, D. Dudek, and A. Wrobel Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression Pharmacol. Rep. 59 2007 778 784 (Pubitemid 351586572)
30. Z. Rogoz, G. Skuza, and B. Legutko Repeated co-treatment with fluoxetine and amantadine induces brain-derived neurotrophic factor gene expression in rats Pharmacol. Rep. 60 2008 817 826
31. P. Rojas, M. Altagracia, J. Kravsov, and C. Rios Partially protective effect of amantadine in the MPTP model of parkinson's disease Proc. West. Pharmacol. Soc. 35 1992 33 35
32. A. Roman, Z. Rogoz, M. Kubera, D. Nawrat, and I. Nalepa Concomitant administration of fluoxetine and amantadine modulates the activity of peritoneal macrophages of rats subjected to a forced swimming test Pharmacol. Rep. 61 2009 1069 1077
33. R.S. Schwab, A.C. England Jr., D.C. Poskanzer, and R.R. Young Amantadine in the treatment of parkinson's disease JAMA 208 1969 1168 1170
34. P.K. Sonsalla, G.D. Zeevalk, L. Manzino, A. Giovanni, and W.J. Nicklas MK-801 fails to protect against the dopaminergic neuropathology produced by systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice or intranigral 1-methyl-4-phenylpyridinium in rats J. Neurochem. 58 1992 1979 1982
35. R.J. Uitti, A.H. Rajput, J.E. Ahlskog, K.P. Offord, D.R. Schroeder, M.M. Ho, M. Prasad, A. Rajput, and P. Basran Amantadine treatment is an independent predictor of improved survival in parkinson's disease Neurology 46 1996 1551 1556 (Pubitemid 26185770)
36. S. Vale Current management of the cognitive dysfunction in parkinson's disease: how far have we come? Exp. Biol. Med. (Maywood) 233 2008 941 951
37. A.L. Wang, Y.M. Liou, C.R. Pawlak, and Y.J. Ho Involvement of NMDA receptors in both MPTP-induced neuroinflammation and deficits in episodic-like memory in wistar rats Behav. Brain Res. 208 2010 38 46
38. M. Weller, F. Finiels-Marlier, and S.M. Paul NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine Brain Res. 613 1993 143 148 (Pubitemid 23170364)
39. G.L. Wenk, W. Danysz, and S.L. Mobley MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis Eur. J. Pharmacol. 293 1995 267 270
40. E. Wolf, K. Seppi, R. Katzenschlager, G. Hochschorner, G. Ransmayr, P. Schwingenschuh, E. Ott, I. Kloiber, D. Haubenberger, E. Auff, and W. Poewe Long-term antidyskinetic efficacy of amantadine in parkinson's disease Mov. Disord. 25 2010 1357 1363
41. H.M. Wu, N.S. Tzeng, L. Qian, S.J. Wei, X. Hu, S.H. Chen, S.M. Rawls, P. Flood, J.S. Hong, and R.B. Lu Novel neuroprotective mechanisms of memantine: increase in neurotrophic factor release from astroglia and anti-inflammation by preventing microglial activation Neuropsychopharmacology 34 2009 2344 2357